We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform...
IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May...
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured in Nature Communications support...
Research collaboration leverages Oncorusβ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoongβs mRNA expertiseOpportunity for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.12055 | 0.12055 | 0.12055 | 0 | 0 | CS |
4 | 0 | 0 | 0.12055 | 0.12055 | 0.12055 | 0 | 0 | CS |
12 | 0 | 0 | 0.12055 | 0.12055 | 0.12055 | 0 | 0 | CS |
26 | 0 | 0 | 0.12055 | 0.12055 | 0.12055 | 0 | 0 | CS |
52 | 0 | 0 | 0.12055 | 0.12055 | 0.12055 | 0 | 0 | CS |
156 | -9.52945 | -98.7507772021 | 9.65 | 11.8099 | 0.0666 | 456221 | 0.57137877 | CS |
260 | -15.37945 | -99.2222580645 | 15.5 | 37.8603 | 0.0666 | 378817 | 2.1250525 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions